News

The speed of adoption of new practices in medicine is extremely slow. We need systems to test new protocols, make sure they’re safe and effective, and get them out into the world more rapidly.

The FDA may approve KarXT, an antipsychotic that does not have the side effects of some other antipsychotics because it does not affect dopamine receptors.

A breakdown of recent survey results revealing which benefits employers plan to keep and what they are looking to add in 2025.

Previous acupuncture studies have focused on European and American women, but little was known about breast cancer patients in Asia.

Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, shared the results found from his organization's latest report on how many consumers are switching their healthcare providers and insurance payers. In the interview, he touched on some of the main drivers to consumers leaving and solutions on how payer and provider groups can turn things around.

The newspaper’s investigation, which included interviewing 300 peole, found that pharmacy benefit manager often act in their own financial interest by overcharging employers and government programs.

Women with HIV are more affected by stigma, gender inequality and socioeconomic status when compared to men with HIV.

Experts on AI spoke about strategies and tactics for implementing artificial intelligence that would assuage worries and build trust during a keynote session at AHIP annual meeting.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

EndeavorOTC costs $24.99 monthly or $129.99 annually.

Physicians in a new survey by the American Medical Association said prior authorization leads to delayed care and a high administration burden for physician practices.

Adherence measures developed by the Pharmacy Quality Alliance (PQA) are an important part of the Medicare Part D Star Ratings program. PQA has launched a Health Equity Technical Expert Panel to provide input on specific approaches to ensuring PQA’s measures support equitable health care.

In a recent announcement, the virtual healthcare provider shared the expansion can offer patients access to a number of clinical services with standard copays, ensuring they receive affordable, high-quality primary care whenever needed.

Congressional Budget Office analysts say that Medicaid unwinding, immigration and scheduled end of ACA premium subsidies are factors in the increase.

A recent industry survey conducted by HealthEdge provides insight into how health insurance consumers in the United States feel about their current coverage.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

The new 2 mL autoinjector offers a more convenient option for adult patients by reducing the number of required injections by half compared to the pre-filled syringe.

Even though value-based care has been talked about for a long time, it may not be the end.

In 2024, there have been two common health plan issues brought up by employers.

Harvard researcher Zirui Song says research findings show that nospitals higher prices and lower quality.

Type 2 diabetes patients ages 10 and up can now take Farxiga.

Three speakers, three different takes on the state of U.S. healthcare and what ails it.

In an interview prior to the AHIP 2024 conference in Las Vegas, MHE spoke with Sachin H. Jain, M.D.,MBA, CEO, SCAN Group and SCAN Health Plan, who acknowledged that while SCAN isn't perfect, they are ahead in simplifying healthcare by recognizing their role in the problem.

CDC Director Mandy K. Cohen spabout the agency modernizing data and working with payers and other parts of the healthcare system at the AHIP meeting in Las Vegas.

In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about how GLP-1 agonist drugs like Wegovy and Zepbound are changing the paradigm for weight loss.

Study results may change the understanding and treatment of hormone-based treatment of primary ovarian insufficiency based on genetics.

Pharmacy benefit managers (PBMs) are slowly coming around and putting biosimilars on their formularies. IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion.

An updated draft guidance says that promotional materials that suggest a biosimilar or reference product is superior “are likely to be false or misleading.” The agency has also warned against making comparisons between biosimilars and those with the interchangeable designation.